151 results about "Osteosarcoma" patented technology

The invention relates to the field of natural products, in particular to a dimer compound of guaiane type sesquiterpenes and uric acid as well as an extraction and separation method and application of the dimer compound. According to the invention, a new dimer compound of guaiane type sesquiterpene and uric acid is extracted and separated from carpesium abrotanoides in Guizhou, and it is found that the dimer compound has relatively strong anti-tumor activity. The compound has strong inhibitory activity on breast cancer, prostate cancer, nasopharynx cancer, liver cancer, lung cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, skin cancer, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer, and provides an optional scheme for broad-spectrum anti-cancer drugs. Moreover, in human prostate cancer cells PC3, human cervical cancer cells Hela, human liver cancer cells HepG2 and human glioma cells U87 which are resistant to paclitaxel, the compound also shows strong anti-cancer activity, which indicates that the compound has the potential of treating patients resistant to paclitaxel.

This invention relates to the field of anticancer drugs, and more particularly to an indole-3-aryl ketone derivative, its preparation method, and its applications. The indole-3-aryl ketone derivative is compound I-VI, which can be used to prepare drugs for the prevention and / or treatment of cancer, including at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, ovarian cancer, kidney cancer, and esophageal cancer. This invention screened the activity of various compounds and, for the first time, discovered that compound I-VI exhibits excellent inhibitory activity against multiple different types of human cancer cells, providing a potential option for broad-spectrum anticancer drugs.

The invention relates to the technical field of image recognition, in particular to an osteosarcoma image intelligent recognition and classification method and system based on an image recognition model. The method comprises the following steps: collecting a tumor image and carrying out multi-sequence disturbance equilibrium enhancement to generate an enhanced block tumor image, then obtaining a color standardized image through color space transformation remapping, then extracting a tumor region image and carrying out contrast inversion processing, reconstructing a tumor feature image, and finally, carrying out multi-sequence disturbance equilibrium enhancement on the tumor feature image. Based on a preset image recognition model, tumor edge features are recognized, the edge rule degree is determined, preliminary classification is carried out, a benign tumor image is obtained, surrounding metabolite signal features of the benign tumor image are analyzed, a benign reference group is formed through combination, metabolism state comparison is carried out on tumor feature images, and metabolism difference data are generated. And performing category correction according to the metabolic state mapping data so as to identify the osteosarcoma category. According to the invention, intelligent analysis of tumor features is realized, the image processing flow is optimized, and the processing efficiency is improved.

There are disclosed inter alia polypeptides and nucleic acids encoding said polypeptides which are useful in the treatment, prevention and diagnosis of cancer, particularly ovarian cancer, osteosarcoma, colon cancer, breast cancer, skin cancer, melanoma, esophageal cancer, esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESSC), particularly esophageal cancer, or EAC or ESSC.

The invention discloses a pelvic soft osteosarcoma MRI (Magnetic Resonance Imaging) segmentation method based on edge-guided multi-scale fusion. The method comprises the following steps: firstly, acquiring an MRI image of a patient with soft osteosarcoma of pelvis, and preprocessing the image; and then, constructing a pelvic soft osteosarcoma MRI segmentation network model, namely an EMU-Net segmentation network, based on edge-guided multi-scale fusion. And training the network by using the preprocessed training data, inputting a pelvic soft osteosarcoma MRI image to be segmented into the trained network, outputting a corresponding segmentation probability graph, and obtaining a final tumor segmentation mask by setting a threshold value. The method not only effectively overcomes the clinical segmentation bottleneck, but also realizes full-automatic and high-efficiency precise segmentation by means of an end-to-end deep learning architecture, and has remarkable advantages in the aspects of precision and robustness.

The invention relates to the technical field of image recognition, in particular to a multi-scale osteosarcoma CT image lesion area detection method based on feature distillation. The method comprises the following steps: acquiring a multi-scale osteosarcoma CT image and an attachment area image, performing forged image difference reduction to generate a unified CT image, reconstructing a three-dimensional tumor body form, extracting a bone attachment structure, performing relocation registration to obtain tumor body relocation data, and then generating a simulation attachment area framework based on the data, the method comprises the following steps: performing static feature distillation on a three-dimensional tumor body form to obtain an edge contour, defining an initial attachment area frame, performing feature comparison through a historical contour image to extract form change, evaluating the erosion degree of the attachment frame, and finally screening candidate lesion areas and positioning osteosarcoma lesion areas according to change areas. According to the invention, more efficient multi-source heterogeneous image data integration, more accurate three-dimensional tumor simulation reconstruction and clearer lesion area detection are realized.

The invention relates to the field of antitumor drugs, in particular to a thiophene acetyl tetrahydro-beta-carboline compound and application thereof. The thiophene acetyl tetrahydro-beta-carboline compound or the pharmaceutically acceptable salt thereof, and the pharmaceutical composition containing the compound can be used for preparing medicines for preventing and / or treating various cancers. The cancer is at least one of breast cancer, lung cancer, osteosarcoma, melanoma, gastric cancer, pancreatic cancer, kidney cancer, glioma and ovarian cancer. Activity screening is carried out on various compounds, it is found for the first time that the 12 compounds provided by the invention have remarkable broad-spectrum inhibitory activity on various human cancer cell lines, and key candidate compounds are provided for developing novel anti-cancer drugs.

The invention relates to application of an SLC30A9 inhibitor in preparation of an anti-tumor medicine, and belongs to the technical field of biological medicines. The invention provides an application of an SLC30A9 inhibitor in preparation of an anti-tumor drug. The expression of SLC30A9 is down-regulated to activate a cGAS-STING-NF-kappa B pathway, so that apoptosis of osteosarcoma cells is promoted, killing of the osteosarcoma cells by MTX is enhanced, and sensitivity of the osteosarcoma cells to MTX chemotherapy is recovered. Through combined application of SLC30A9 knock-down, a cGAS-STNG-NF-kappa B pathway agonist and MTX for chemotherapy, the killing effect of MTX on osteosarcoma cells can be remarkably enhanced, tumor cell proliferation is inhibited, and the treatment effect is improved. The core effect of the SLC30A9 in an osteosarcoma chemotherapy drug resistance mechanism is defined, and a theoretical basis and a technical support are provided for subsequent development of targeted drugs aiming at a cGAS-STNG-NF-kappa B pathway.

GD2 specific chimeric antigen receptor effector cells for the treatment of solid tumors, possibly in combination with an enhancer of a Zeste homolog 2 (EZH2) inhibitor. The invention relates to a GD2-specific chimeric antigen receptor (GD2. CAR) effector cell for use in the treatment of solid tumors, in particular in the treatment of extracranial GD2 + tumors, such as soft tissue sarcoma and osteosarcoma, neuroblastoma, melanoma, lung cancer, bladder cancer and retinoblastoma, and brain tumors. In addition, the present invention also relates to the use of the GD2. CAR genetically modified effector cell in combination with an enhancer of a Zeste homolog 2 (EZH2) inhibitor for the treatment of solid tumors.

Aspects of this invention are related to the use of N-desmethyl ruboxistaurin and pharmaceutically acceptable formulations thereof to modulate RSK signaling. Some aspects of the invention relate to the use of N-desmethyl ruboxistaurin to inhibit RSK. Some aspects of the invention provide methods of using N-desmethyl ruboxistaurin in the treatment of subjects with cancer, including breast cancer, ovarian cancer, prostate cancer, lung cancer, hepatocellular carcinoma, colorectal cancer, melanoma, osteosarcoma, myeloproliferative neoplasms, leukemia, and bladder cancer. The disclosed methods extend beyond disease treatment, including supportive care during radiation chemotherapy and prevention of cancer relapse. N-desmethyl ruboxistaurin administration, alone or in combination with other cancer therapies, inhibits RSK and shows a safety profile that supports its long-term use.

This disclosure provides compounds of formula (I) or pharmaceutically acceptable salts thereof, methods for preparing the same, and their use in the treatment and / or diagnosis of cancers such as neuroblastoma, prostate cancer, pancreatic cancer, leukemia, osteosarcoma, hepatoblastoma, lung cancer, colon cancer, breast cancer, skin cancer, thyroid cancer, and / or rhabdoid cancer. JPEG2026522940000099.jpg50170

The disclosure relates to the field of gene therapy for the treatment of an osteosarcoma using splice-switching oligonucleotides. Increased expression of INSR-A, an isoform frequently expressed in cancer, can effectively evade current therapeutic mechanisms and contribute to resistance in cancer patients. As a means to address the ability of cancer to evade therapies through this mechanism, Applicant provides a polynucleotide comprising a promoter, for example a U7 or a U1 promoter, and a first splice-switching oligonucleotide (SSO) that targets a regulatory element of an insulin receptor (JR).

The invention provides application of a bisindole compound XQ-016 in treatment of osteosarcoma, and belongs to the technical field of biological medicines. The bisindole compound XQ-016 can inhibit proliferation, migration and invasion of tumor cells by adjusting an STAT3 / p53 signal channel, inducing G1 phase cell cycle arrest and inhibiting MMP2 / MMP9 expression, shows remarkable anti-tumor activity, is a promising treatment choice in tumor treatment, and can be used as an effective component in anti-tumor drugs.

The application discloses a kind of thieno [2, 3-c] pyrazole compounds in preparation antitumor drug purposes, belong to pharmaceutical chemistry technical field.The application provides a kind of small molecule skeleton thieno [2, 3-c] pyrazole compound I and II, compound I is 2-oxo benzo [d] [1, 3] oxathiole-6-yl 1-(3-fluorophenyl)-3-methyl-1H-thieno [2, 3-c] pyrazole-5-carboxylate.Compound II is 1-(4-chlorophenyl)-N-[4-((4-ethylpiperazine-1-yl)methyl)phenyl]-3-methyl-1H-thieno [2, 3-c] pyrazole-5-formyl.Both have strong antitumor activity.Compound II has strong inhibition to a variety of human tumor cells, such as bone sarcoma MG63, breast cancer HCC1806, liver cancer LM3, lung cancer A549, colorectal cancer HCT-8 and the like, provides new candidate compounds for broad-spectrum antitumor drugs.

The invention belongs to the technical field of diagnosis and treatment of osteosarcoma, and particularly relates to application of a C1QTNF1-AS1 / miR-346-LDHA / PDK regulation axis in diagnosis and treatment of osteosarcoma, a full-chain technical system of'diagnostic marker-double-target intervention-clinical transformation 'is constructed on the basis of the C1QTNF1-AS1 / miR-346-LDHA / PDK regulation axis, and accurate diagnosis and metabolic intervention of osteosarcoma are realized through multi-dimensional experimental verification; in the diagnosis, a C1QTNF1-AS1 / miR-346 combined detection kit based on qPCR is applied to early screening of osteosarcoma; according to the treatment application, the C1QTNF1-AS1 adenovirus and the miR-346 lipidosome are used in a combined manner, and LDHA and PDK1 are synchronously inhibited, so that the Warburg effect related metabolic flux is intervened.

The present invention provides a composition for use in a method of treating osteosarcoma, Ewing sarcoma and / or a metastatic cancer originating from osteosarcoma or Ewing sarcoma. The present invention also provides a method of treating a cancer selected from the group consisting of osteosarcoma, Ewing sarcoma, a metastatic cancer originating from an osteosarcoma and a metastatic cancer originating from Ewing sarcoma.

The invention relates to application of Nogo-B protein in preparation of a medicine serving as an anti-osteosarcoma target spot. The invention discloses an alpha-hydroxyl / alkoxy / amino-beta-amino derivative, a synthesis method thereof and application of Nogo-B protein serving as a new osteosarcoma target, an osteosarcoma diagnostic reagent and a small-molecule inhibitor 4v serving as an osteosarcoma targeting drug. A diazo compound, water / alcohol / amide and imine are used as raw materials, rhodium acetate is used as a catalyst, a product is obtained in an organic solvent through a one-step reaction with high selectivity and high yield, then the small-molecule inhibitor 4v is obtained through osteosarcoma cell surface screening, a new osteosarcoma target Nogo-B is proposed based on a proteomics analysis technology, and the new target Nogo-B is used for inhibiting osteosarcoma. The effects of inhibiting cell proliferation and migration and tumor growth can be achieved through experiments such as knockout of Nogo-B protein. The invention discloses a novel application of Nogo-B protein. The Nogo-B protein is used for preventing, relieving and treating osteosarcoma and osteosarcoma-related complications of individuals in need. Also disclosed are methods of diagnosing, treating, and monitoring osteosarcoma or methods of inhibiting osteosarcoma, and methods of screening for osteosarcoma inhibitors.

The invention relates to anti-GD2 antibody-drug conjugates, compositions comprising the same and uses thereof in the treatment of osteosarcoma.

The invention discloses an application of targeted improvement of a high-potassium microenvironment in osteosarcoma immunotherapy, vanadium disulfide nano-particles are synthesized by taking vanadyl acetylacetonate as a raw material and adopting a high-temperature oil phase method, the particles can be accelerated to decompose at 42 DEG C or above so as to release hydrogen sulfide and vanadate, the vanadate can be specifically combined with E2 conformation of Na < + >-K < + >-ATP enzyme, and thus the stability of the particles is improved. According to the present invention, the HSP protein is released, the conversion of the HSP protein to E1 conformation is blocked, the continuous inward flow of K < + > is inhibited, such that the potassium ion concentration in the T cell is reduced, the function inhibition on the T cell is relieved, and the released hydrogen sulfide can further enhance the thermal effect by inhibiting the HSP protein so as to form the ion regulation-immune activation dual mechanism to improve the T cell killing ability. According to the scheme, the high potassium ion level of the osteosarcoma microenvironment is regulated and controlled through vanadate, hydrogen sulfide can enhance immune response and improve the anti-tumor function of T cells by enhancing the heat effect and the synergistic effect of vanadate, and an efficient and low-toxicity new strategy is provided for osteosarcoma treatment.

The invention relates to a polyethylene glycol medicine as well as a preparation method and application thereof. Specifically, the invention relates to a compound as shown in a formula I or pharmaceutically acceptable salt thereof, an intermediate compound as shown in a formula II-XX, a method for preparing the compound, and an application of the compound in tumor resistance. Biological tests show that the compound has a remarkable inhibition effect on tumors such as breast cancer, non-small cell lung cancer, melanoma, oral squamous cell carcinoma and osteosarcoma.

There are disclosed inter alia polypeptides and nucleic acids encoding said polypeptides which are useful in the treatment, prevention and diagnosis of cancer, particularly ovarian cancer, gastrointestinal cancer, pancreatic cancer, prostate cancer, stromal cancer, osteosarcoma, colon cancer, breast cancer, skin cancer, melanoma, esophageal cancer, esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESSC), particularly esophageal cancer, or EAC or ESSC.

The invention relates to the technical field of biological medicines, and particularly discloses a nanocapsule SMCPM and application thereof in medicines for treating or preventing osteosarcoma and pulmonary metastasis. The SMCPM is composed of a photosensitizer Ce6 carried by mesoporous silicon oxide-manganese oxide particles, an NRF2 inhibitor ML385 and an OS targeting peptide PT-7. Experiments prove that the SMCPM is high in penetrating power and strong in cell killing effect; by down-regulating NRF2 expression and reversing nuclear translocation, a biochemical inhibitory microenvironment can be effectively repaired, the tolerance of cells to active oxygen and epithelial-mesenchymal transition activated and induced by a NOTCH1 signal axis are remarkably reduced, the oxidative stress level of the cells is enhanced, and PIT-induced immunogenic cell death is promoted; the released Mn < 2 + > and double-stranded DNA can regulate and control an immunosuppressive microenvironment by activating an STING pathway in cells, thereby inhibiting the growth of osteosarcoma and preventing lung metastasis.

Disclosed are purine derivatives of formulae (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods involving the inventive compounds or compositions for treating and / or preventing cell proliferative diseases including certain cancers of breast, brain, ovarian, lung, colorectal cancer, leukemias, lymphoma, melanoma, multiple myeloma, Ewing's sarcoma, osteosarcoma and inflammatory and myotonic dystrophy type 1 diseases in a mammal. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of kinases, such as a cyclin-dependent kinases (CDK) (e.g., CDK12 / 13), and therefore, induce potent antiproliferative and apoptotic effects and / or inhibit transcription in the subject.

The utility model provides an osteosarcoma in-vitro culture chip which comprises a carrier plate, an outlet hole and at least two inlet holes are formed in the two ends of the carrier plate respectively, the inlet holes are higher than the outlet hole, and a mixing channel area, a concentration gradient forming area, a tissue culture area and a liquid storage buffer area which are communicated and are gradually decreased in height are sequentially arranged between the inlet holes and the outlet holes. The concentration mixing channel area comprises a mixing channel, inflow ends and outflow ends which are communicated, the inflow ends and the outflow ends are arranged on the two sides of the mixing channel respectively, the inflow ends are arranged between the adjacent outflow ends in the length direction of the mixing channel, and the number of the outflow ends of the concentration mixing channel area is one more than that of the inflow ends. The multiple concentration gradient forming areas are arranged side by side, all the inlet holes are communicated with all the inflow ends through the flow channels, all the outflow ends are communicated with all the concentration gradient forming areas through the flow channels, and the problem that the medicine concentration screening efficiency is low during osteosarcoma in-vitro culture is solved.

The present application relates to a kind of polycyclic polyketone compounds and its preparation method, pharmaceutical composition and application, the chemical structure type of the polycyclic polyketone compound is different from existing anti-osteosarcoma chemotherapy drug, it is compound with brand-new structure, while inventor finds that the polycyclic polyketone compound has significant anti-osteosarcoma cell 143B and U2OS activity by experiment, the anti-osteosarcoma activity of part compound is better than positive control drug, the result further indicates that the polycyclic polyketone compound of the present application can significantly inhibit the growth of osteosarcoma, and it is expected to develop into a new type of anti-osteosarcoma drug, can be used for treating osteosarcoma and the disease caused by bone and joint pain and lung disease.Further, the synthesis route of the polycyclic polyketone compound used in the present application is efficient and simple, and has good raw material economy.

This invention discloses a nano-aluminum formulation of doxorubicin / zoledronic acid, its preparation method, and its application. The preparation method includes the following steps: S1: Adding an aqueous solution of zoledronic acid with a pH of 4-6 to the aqueous solution of nano-aluminum, stirring to obtain zoledronic acid-nano-aluminum; S2: Adding an aqueous solution of doxorubicin to the aqueous solution of zoledronic acid-nano-aluminum, stirring to obtain the doxorubicin / zoledronic acid nano-aluminum formulation. The DOX / ZA-Al-nano formulation of this invention can effectively inhibit tumor cell growth by promoting greater entry of doxorubicin into cells and rapid entry into the cell nucleus, and can be used for the combination therapy of osteosarcoma. Furthermore, the preparation method of this invention is simple, the reaction conditions are mild, and it is easy to operate, optimizing the preparation process and application scheme of nano-aluminum, and has the prospect of industrialization.

The invention discloses application of a thieno [2, 3-c] pyrazole compound in preparation of antitumor drugs, and belongs to the technical field of medical chemistry. The invention provides a small molecular skeleton thieno [2, 3-c] pyrazole compound I and a small molecular skeleton thieno [2, 3-c] pyrazole compound II, and the compound I is 2-oxobenzo [d] [1, 3] oxathiacyclopentane-6-yl 1-(3-fluorophenyl)-3-methyl-1H-thieno [2, 3-c] pyrazole-5-formate. And the compound II is 1-(4-chlorphenyl)-N-[4-((4-ethyl piperazine-1-yl) methyl) phenyl]-3-methyl-1H-thieno [2, 3-c] pyrazole-5-formyl. The two compounds have relatively strong anti-tumor activity. Wherein the compound II has a relatively strong inhibition effect on various human tumor cells such as osteosarcoma MG63, breast cancer HCC1806, liver cancer LM3, lung cancer A549, colorectal cancer HCT-8 and the like, and a new candidate compound is provided for broad-spectrum antitumor drugs.

An injectable hydrogel for inhibiting osteosarcoma growth and its component preparation method are disclosed. The hydrogel is composed of curcumin nanoparticles, nano-hydroxyapatite, and methacryloxychitosan. This injectable hydrogel for inhibiting osteosarcoma growth combines the antitumor properties of curcumin nanoparticles, the osteogenic ability and good mechanical strength of nano-hydroxyapatite, and the porous structure and injectability of methacryloxychitosan. This injectable hydrogel for inhibiting osteosarcoma growth exhibits a significant killing effect on osteosarcoma cells and simultaneously promotes the proliferation of mouse embryonic pre-osteoblasts. Through its synergistic antitumor and osteogenic dual functions, this hydrogel shows promising application prospects in postoperative treatment of osteosarcoma.

The invention discloses a preparation method of an injectable bismuth-based metal repairing agent, which comprises the following steps of: putting weighed bismuth, indium, tin and zinc metals into a crucible, putting the crucible into a vacuum high-temperature smelting furnace, heating the mixed metals in a vacuum environment until the mixed metals are completely molten by adjusting the smelting temperature, stirring and shaking the formed molten alloy, and then cooling the molten alloy to obtain the injectable bismuth-based metal repairing agent. And ensuring that four elements of bismuth, indium, tin and zinc are uniformly distributed in the alloy, naturally cooling the fully and uniformly mixed molten alloy, and solidifying to obtain the solid injectable bismuth-based metal repairing agent. The repairing agent can be used for treating osteosarcoma, firstly, the repairing agent is injected into a medullary cavity, so that the repairing agent is solidified in situ to form an internal fixing structure, then a magnetocaloric effect is triggered through an alternating magnetic field to induce osteosarcoma immunogenic death, and integrated treatment of tumor removal and bone repair is achieved. According to the scheme, the biological safety and the osseointegration function are achieved, the magnetic-thermal conversion process is efficient, and the good treatment effect on osteosarcoma is achieved.

The invention relates to an aloe-emodin piperazine derivative as well as a preparation method and application thereof, and belongs to the technical field of medicine synthesis. The aloe-emodin piperazine derivative is obtained by taking aloe-emodin as a raw material, substituting 15-site alcoholic hydroxyl of the aloe-emodin with piperazine and then connecting the 15-site alcoholic hydroxyl with a natural compound with anti-tumor activity and a derivative of the natural compound by utilizing different connecting arms. In-vitro anti-tumor experiments of the aloe-emodin piperazine derivative show that the aloe-emodin piperazine derivative has good anti-tumor activity on human cervical cancer cells (HeLa), human liver cancer cells (HepG2), human lung cancer cells (A549) and human osteosarcoma cells (U2OS), is expected to be developed into drugs for treating cervical cancer, osteosarcoma, lung cancer or liver cancer and other cancers, and has wide clinical application prospects.